Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16591170 | 1.00 | GRM2 (0.48) | GRM2SLC6A4MAPTALDH1A1GAA | |
| SCHEMBL16591225 | 0.89 | GRM2 (0.50) | GRM2MAPTALDH1A1GAASYK | |
| SCHEMBL17985198 | 0.89 | GRM2 (0.50) | GRM2MAPTALDH1A1GAASYK | |
| SCHEMBL16590813 | 0.89 | GRM2 (0.49) | GRM2 | |
| SCHEMBL17985290 | 0.89 | GRM2 (0.49) | GRM2 | |
| SCHEMBL18016779 | 0.81 | SLC6A4 (0.38) | GRM2SLC6A4ELOVL1GRIN2B | |
| SCHEMBL17985192 | 0.81 | GRM2 (0.51) | GRM2SLC6A4ELOVL1SYKSLC6A2 | |
| SCHEMBL17985193 | 0.81 | GRM2 (0.51) | GRM2SLC6A4ELOVL1SYKSLC6A2 | |
| SCHEMBL740326 | 0.72 | PPIA (0.45) | GRM2MAPTSYK | |
| SCHEMBL748593 | 0.71 | GRM2 (0.48) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | GRM2, GRIK2, GRIA2 | GRM2 1/4885SLC6A4 906/4885MAPT 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.